Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × pegfilgrastim × Sarcoma × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 2 Sarcoma 1 Genitourinary 1

Conditions

Sarcoma 10 Rhabdomyosarcoma 7 Sarcoma, Ewing 4 Osteosarcoma 4 Sarcoma, Synovial 3 Neurofibrosarcoma 3 Lymphoma, Large B-Cell, Diffuse 3 Dendritic Cell Sarcoma, Interdigitating 3 Neuroectodermal Tumors, Primitive, Peripheral 2 Lymphoma 2 Liposarcoma 2 Leiomyosarcoma 2 Histiocytoma, Malignant Fibrous 2 Fibrosarcoma 2 Bone Neoplasms 2 Neutropenia 1 Neoplasms 1 Neoplasm Metastasis 1 Malignant mesenchymal tumor 1 Hemangiosarcoma 1 Heart Failure 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Desmoplastic Small Round Cell Tumor 1 Chondrosarcoma 1 Cardiotoxicity 1 Brain Neoplasms 1

Interventions

pembrolizumab 8 Ibandronic Acid 8 Gemcitabine 8 Doxorubicin 8 Cyclophosphamide 8 Specimen Handling 7 pazopanib 6 Biopsy 6 Radiosurgery 5 Nivolumab 5 Magnetic Resonance Spectroscopy 5 Imatinib Mesylate 5 Bevacizumab 5 regorafenib 4 Zoledronic Acid 4 Irinotecan 4 Docetaxel 4 Radiation 3 Ifosfamide 3 Cryosurgery 3 Carboplatin 3 trastuzumab deruxtecan 2 trametinib 2 temsirolimus 2 sargramostim 2 olaparib 2 masitinib 2 ganitumab 2 futibatinib 2 conatumumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01879085 2022-09-21

GemTax

University of Pittsburgh

Phase 1/2 Completed

37 enrolled 17 charts

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡